368 related articles for article (PubMed ID: 24667108)
1. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
3. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
[TBL] [Abstract][Full Text] [Related]
4. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
[TBL] [Abstract][Full Text] [Related]
6. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma.
Baliou E; Nonni A; Keramopoulos D; Ragos V; Tsiambas E; Patsouris E; Pavlakis K
J BUON; 2016; 21(5):1099-1103. PubMed ID: 27837610
[TBL] [Abstract][Full Text] [Related]
8. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
9. [Study of mdm2 gene amplification in primary breast tumors].
Fontana X; Ferrari P; Abbes M; Monticelli J; Namer M; Bussière F
Bull Cancer; 1994 Jul; 81(7):587-92. PubMed ID: 7742600
[TBL] [Abstract][Full Text] [Related]
10. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.
Egorova O; Lau HH; McGraphery K; Sheng Y
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075226
[TBL] [Abstract][Full Text] [Related]
11. Mdmx promotes genomic instability independent of p53 and Mdm2.
Carrillo AM; Bouska A; Arrate MP; Eischen CM
Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
[TBL] [Abstract][Full Text] [Related]
12. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression.
Carroll PE; Okuda M; Horn HF; Biddinger P; Stambrook PJ; Gleich LL; Li YQ; Tarapore P; Fukasawa K
Oncogene; 1999 Mar; 18(11):1935-44. PubMed ID: 10208415
[TBL] [Abstract][Full Text] [Related]
13. Regulation of p53: a collaboration between Mdm2 and Mdmx.
Pei D; Zhang Y; Zheng J
Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
[TBL] [Abstract][Full Text] [Related]
14. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
16. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
17. Mdmx and Mdm2: brothers in arms?
Marine JC; Jochemsen AG
Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
[TBL] [Abstract][Full Text] [Related]
18. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.
Wang X; Wang J; Jiang X
J Biol Chem; 2011 Jul; 286(27):23725-34. PubMed ID: 21572037
[TBL] [Abstract][Full Text] [Related]
19. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
Cai X; Yuan ZM
J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
[TBL] [Abstract][Full Text] [Related]
20. mdm2 gene alterations and mdm2 protein expression in breast carcinomas.
Marchetti A; Buttitta F; Girlando S; Dalla Palma P; Pellegrini S; Fina P; Doglioni C; Bevilacqua G; Barbareschi M
J Pathol; 1995 Jan; 175(1):31-8. PubMed ID: 7891224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]